Pharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Your Basket's Financial Footprint
Market capitalisation breakdown for the 'Pharma Onshoring' basket, highlighting total market cap and concentration among largest constituents.
- Large-cap dominance suggests lower volatility and broader market-tracking tendencies, implying generally steadier performance and reduced risk.
- Use this basket as a core holding for diversified exposure, not as a speculative or concentrated growth bet.
- Expect steady, long-term value accumulation rather than rapid, explosive short-term gains; returns are likely moderate.
MRK: $215.61B
PFE: $140.38B
LLY: $765.65B
- Other
About This Group of Stocks
Our Expert Thinking
Merck's massive $3 billion Virginia plant investment signals a fundamental shift towards domestic pharmaceutical production. This trend is driven by supply chain vulnerabilities exposed during recent global disruptions and growing government emphasis on healthcare security. We believe this creates a multi-year investment opportunity across the entire pharmaceutical manufacturing ecosystem.
What You Need to Know
This group includes both pharmaceutical giants making major onshoring investments and the supporting companies that enable domestic production. The theme spans drug manufacturers, industrial construction firms, specialised equipment providers, and logistics companies. It's a long-term play on rebuilding America's pharmaceutical infrastructure with potential for sustained growth.
Why These Stocks
These companies were handpicked by professional analysts based on their direct involvement in or benefit from the pharmaceutical onshoring trend. Each represents a different piece of the value chain, from major pharma companies leading the charge to essential service providers supporting the transition to domestic manufacturing.
Why You'll Want to Watch These Stocks
Manufacturing Renaissance
Merck's $3 billion Virginia plant is just the beginning. This massive investment signals a fundamental shift towards domestic pharmaceutical production that could reshape the entire industry.
Supply Chain Security
Recent global disruptions exposed critical vulnerabilities in drug supply chains. Companies leading the onshoring charge are positioning themselves as essential partners in America's healthcare security.
Multi-Year Growth Story
This isn't a quick trend but a structural shift requiring years of investment and development. Early movers in pharmaceutical onshoring could benefit from sustained tailwinds and government support.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Boeing Forced Sale Impact | Defense Stocks 2025
The FTC's requirement for Boeing to sell parts of Spirit AeroSystems to approve their merger opens up the aerospace supply chain. This creates investment opportunities in other component manufacturers and defense contractors poised to benefit from a more competitive landscape.
Media Takeover Race Heats Up in 2025
Paramount Skydance has intensified the bidding war for Warner Bros. Discovery by increasing its breakup fee, signaling a strong commitment to the acquisition. This highlights a broader trend of consolidation in the media sector, creating potential opportunities among other content producers and M&A service providers.
EU Meta AI Probe: What's Next for Tech Competition
The EU is investigating Meta's practice of blocking rival AI chatbots on WhatsApp, raising significant antitrust concerns. This regulatory pressure could force open the ecosystem, creating a major growth opportunity for independent AI developers and challenging the dominance of Big Tech gatekeepers.